Advertisement
Advertisement
NTLA
Intellia Therapeutics, Inc
13.49
USDSponsored
-0.34
-2.45%
Apr 10, 15:59 UTC -4
Closed
After-Market
13.57
+0.08
+0.59%
NTLA Earnings Reports
Positive Surprise Ratio
NTLA beat 22 of 40 last estimates.
55%
Next Report
Date of Next Report
Apr 30, 2026
Estimate for Q1 26 (Revenue/ EPS)
$14.76M
/-$0.93
Implied change from Q4 25 (Revenue/ EPS)
-35.86%
/+12.05%
Implied change from Q1 25 (Revenue/ EPS)
-11.21%
/-15.45%
Intellia Therapeutics, Inc earnings per share and revenue
On Feb 26, 2026, NTLA reported earnings of -0.83 USD per share (EPS) for Q4 25, beating the estimate of -0.97 USD, resulting in a 14.78% surprise. Revenue reached 23.02 million, compared to an expected 13.04 million, with a 76.49% difference. The market reacted with a +6.41% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 13 analysts forecast an EPS of -0.93 USD, with revenue projected to reach 14.76 million USD, implying an increase of 12.05% EPS, and decrease of -35.86% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Intellia Therapeutics, Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Intellia Therapeutics, Inc reported EPS of -$0.83, beating estimates by 14.78%, and revenue of $23.02M, 76.49% above expectations.
How did the market react to Intellia Therapeutics, Inc's Q4 2025 earnings?
The stock price moved up 6.41%, changed from $13.42 before the earnings release to $14.28 the day after.
When is Intellia Therapeutics, Inc expected to report next?
The next earning report is scheduled for Apr 30, 2026.
What are the forecasts for Intellia Therapeutics, Inc's next earnings report?
Based on 13
analysts, Intellia Therapeutics, Inc is expected to report EPS of -$0.93 and revenue of $14.76M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement